To date, all approaches demonstrating that NLRP3 inhibition improves amyloid burden in AD have been performed using germline deletion of NLRP3 or caspase-1, and to our knowledge this is the first study to demonstrate a potential capacity for NLRP3 inhibition to reduce amyloid burden and/or morphology in the context of a therapeutic paradigm. This evidence concerns the gene NLRP3 and Alzheimer disease.